Immunology & Inflammation

This report summarises what Blossom’s database shows about psychedelics, the immune system and inflammation. It is worth being clear what kind of page this is. It is not a condition page and not a treatment. It is about a mechanism, and a striking hypothesis built on it: that psychedelics are anti-inflammatory, and that this might matter both for inflammatory disease and for how they treat depression. The hypothesis is genuinely interesting. It is also, more than almost any other topic on this site, a story told from animals and cells rather than from people.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a recommendation to take psychedelics, least of all for an inflammatory or autoimmune condition. The anti-inflammatory findings described below come overwhelmingly from laboratory models, not from treated patients, and the human evidence is thin and inconsistent. Read this as an account of a promising mechanism, not of a demonstrated therapy.

The exciting mechanism, and where it comes from

The idea starts with a clean and dramatic result. A psychedelic compound, inhaled, prevented the major features of allergic asthma in mice[1]Am J Physiol Lung (2015), PRECLINICAL (mouse): inhaled (R)-DOI prevents key features of allergic asthma (airway hyper-responsiveness, mucus, inflammation, eosinophils), acting through the serotonin 2A receptor, the same receptor responsible for the psychedelic experience. A follow-up added a genuinely exciting twist: testing more than twenty related compounds, researchers found that how strongly a molecule fought inflammation had nothing to do with how strongly it caused hallucinations[2]ACS Pharmacol Transl Sci (2020), PRECLINICAL (rat): anti-inflammatory potency of 21 5-HT2A agonists does NOT correlate with hallucinogenic potency (a non-hallucinogenic anti-inflammatory route). That dissociation is the seed of a real ambition, an anti-inflammatory drug that hits this receptor without producing a trip.

There is a second, separate mechanism too, centred on DMT and the sigma-1 receptor. In human immune cells in a dish, DMT and 5-MeO-DMT calmed inflammatory signalling and boosted an anti-inflammatory cytokine[3]PLoS ONE (2014), IN VITRO (human dendritic cells): DMT and 5-MeO-DMT suppressed pro-inflammatory cytokines and raised IL-10 via the sigma-1 receptor, and the same pathway protected human nerve cells from oxygen starvation[4]Front Neurosci (2016), IN VITRO (human iPSC neurons/microglia): DMT protects against hypoxia via sigma-1 receptor activation (preclinical) and limited brain damage in rats[5]Neuropharmacology (2021), PRECLINICAL (rat): DMT attenuates spreading depolarisation and neurodegeneration in ischaemic brain via the sigma-1 receptor. Taken together, these are two plausible, well-described ways psychedelics could be anti-inflammatory. The catch is in the phrase that keeps recurring: in mice, in rats, in a dish.

The molecule that carries the story is not a medicine

The most important caveat about the headline mechanism is easy to miss. The compound at the centre of the asthma work, and much of the 5-HT2A anti-inflammatory literature, is a research chemical called DOI. It is a superb laboratory tool, but it is not a clinical drug, has never been developed as a human medicine, and is not what anyone takes. So the chain of reasoning from "5-HT2A activation is powerfully anti-inflammatory in mice" to "psilocybin or LSD will treat inflammatory disease in people" passes through a molecule that is neither psilocybin nor LSD nor a medicine. That is an inference, and a long one, not a demonstrated result.

The point is sharpened by what happens when researchers test the actual psychedelics directly on human immune cells. In at least one careful study, LSD, psilocin, DMT and mescaline produced no relevant direct immune effect at all[6]Front Psychiatry (2023), IN VITRO: LSD, psilocin, DMT and mescaline showed NO relevant direct immune-modulatory effect on human T cells or monocytes (the key negative). That negative result sits awkwardly with the enthusiastic reviews, and an honest account has to give it weight: the drugs people actually use may simply not do, in human immune cells, what the research-chemical and animal literature suggests they should.

In people: small, brief, and contradictory

Where psychedelics have been given to humans and their inflammatory markers measured, the results are a study in inconsistency. One trial found psilocybin acutely lowered the inflammatory cytokine TNF-alpha[7]Brain Behav Immun (2023), psilocybin in 60 healthy volunteers acutely reduced TNF-alpha (other markers unchanged), with IL-6 and CRP modestly lower at day 7; another, also single-dose, found no change in any inflammatory marker[8]Compr Psychoneuroendocrinol (2023), single-dose psilocybin (n=16): NO significant change in hsCRP, TNF or suPAR (all d<=0.31, p>=0.23) — the conflicting human null. For 5-MeO-DMT, a small study found a drop in salivary IL-6[9]Psychopharmacology (2019), inhaled 5-MeO-DMT (n=11) raised cortisol and lowered salivary IL-6 acutely; the changes did not correlate with mental-health ratings, and an MDMA-therapy pilot found small, mixed-direction changes[10]Front Neurosci (2026), MDMA-assisted therapy open-label pilot (n=23 veterans): small, mixed-direction changes in IL-6, CRP and TNF-alpha; preliminary. This is not the footprint of a strong, reliable anti-inflammatory effect; it is the pattern you see when an effect is weak, variable, or not really there.

A specific confound makes even the positive findings hard to interpret. A full psychedelic dose is a major physiological event that sharply raises cortisol, the stress hormone, and cortisol itself shifts inflammatory markers. So a brief change in a cytokine an hour after dosing may be the body’s stress response to an intense experience rather than a direct anti-inflammatory action of the drug. Until studies are designed to separate the two, the human cytokine data cannot bear much weight in either direction.

The inflammation-and-depression idea

The most clinically appealing version of this topic is the proposal that psychedelics ease depression partly by reducing inflammation, since depression is associated with raised inflammatory markers. The best human evidence is the ayahuasca depression trial, in which C-reactive protein fell with treatment and the fall tracked the improvement in mood[11]J Psychopharmacol (2020), ayahuasca TRD RCT: CRP fell with ayahuasca (not placebo) and tracked symptom improvement, but IL-6 was unchanged and biomarkers did NOT predict response. That is the single most supportive human result on the page.

And yet the same study undercuts the strong version of the claim. A second inflammatory marker did not move, and, decisively, the inflammatory markers did not predict who actually got better. If inflammation were the mechanism, you would expect the people whose inflammation fell most to improve most; that link was not established. The honest reading is that inflammation may fall alongside antidepressant recovery without driving it, a correlation, not a demonstrated cause. The inflammation-and-depression hypothesis remains live and worth testing, but it has not been shown to be true in people.

Reading this honestly

So how should you read the immunology story? As one of the field’s most exciting mechanisms and one of its least proven applications. The animal and cell pharmacology is real: activating the serotonin 2A receptor is powerfully anti-inflammatory in models, DMT has a credible sigma-1 mechanism, and the discovery that anti-inflammatory and hallucinogenic effects can be separated is genuinely important, pointing toward a possible non-tripping anti-inflammatory drug. But almost none of this has been shown where it would matter. The headline mechanism rides on a research chemical that is not a medicine; a direct test on human immune cells found nothing; the human cytokine studies are small, brief, contradictory and confounded by the stress of dosing; the one positive human result did not establish inflammation as the cause of benefit; and there is not a single completed trial in any actual inflammatory disease. The most useful thing this literature offers an honest reader is a clear separation between a compelling laboratory hypothesis and a clinical claim that has not been earned. The mechanism deserves serious testing. It does not yet deserve to be called a treatment.